Integrin Alpha V Market Will Generate Record Revenue by 2029

Integrin alpha V market is anticipated to grow at a significant CAGR during the forecast period. Integrins are proteins that function mechanically. They attach to the cell cytoskeleton to the extracellular matrix (ECM), and biochemically through sensing if adhesion has occurred. The integrin family consists of two types of protein including alpha and beta subtypes. Integrin alpha-V is a protein that is encoded by the ITGAV gene in humans. The major factor driving the demand for the global integrin alpha V market is the rising prevalence of the respiratory disease across the globe.

According to the World Health Organization (WHO), Some common chronic respiratory disease includes asthma, occupational lung diseases and pulmonary hypertension. Additionally, as per the same source, asthma is common among children and an estimated 235 million people suffer from it. Furthermore, more than 90% of mortalities from respiratory disease occurs in low income and middle-income countries. Moreover, there is a mortality rate of more than 3 million people with an estimated 6% of all deaths globally. Additionally, integrin alpha V supports in selective retention of lymphocytes in mucosal tissues of the lung. Hence, the rising prevalence of respiratory disease is driving the demand for integrin alpha V, which in turn, is driving the growth of the market.

Some major players operating in the market include Biogen Inc., Merck KGaA, and Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in June 2021, Corbus Pharmaceuticals announced that it is expanding its pipeline in immuno-oncology and fibrotic disease by launching two monoclonal antibodies (mAbs) including CRB-601 and CRB-602. CRB-601 is a high potency anti-alpha V beta 8 (anti-avb8 mAb) antibody, while CRB-602 antibody inhibits both alpha V beta 6 and alpha V beta 8.

To Request a Sample of our Report on Integrin Alpha V Market: https://www.omrglobal.com/request-sample/integrin-alpha-v-market

Market Coverage

• The market number available for - 2022-2030

• Base year- 2022

• Forecast period- 2022-2030

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Biogen Inc., Merck KGaA, and Pfizer Inc., among others.

Integrin Alpha V Market Report by Segment

By Type

· MK-0429

· C-16Y

· 264-RAD

· AC-301

· Others

By Application

· Metabolic Disorders

· Ophthalmology

· Respiratory

· Infectious Disease

· Others

A full Report of Integrin Alpha V Market is Available @ https://www.omrglobal.com/industry-reports/integrin-alpha-v-market

Integrin Alpha V Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.